Clinical trials: High-Risk Cancer
Lymphoma
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
The goal of this clinical research study is to learn if chemotherapy given with rituximab, followed by Ibritumomab tiuxetan (Zevalin), and then followed by rituximab can help to control lymphoma.
- Trial name
- NCT00290511
- Testing
- Fludarabine, Mitoxantrone, Rituximab
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, B-Cell, Relapsed Cancer
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy.
- Conditions
- Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06004167
- Testing
- Adaptive Bridging Radiation Therapy (ABRT)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Bladder Cancer
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
This Phase Ib/II study is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, patient reported outcomes (PROs), and preliminary anti-tumor activity of atezolizumab administered by intravenous (IV)…
- Trial name
- NCT02792192
- Testing
- Atezolizumab, Bacille Calmette-Guérin
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Gliomas
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
Data from the wistar institute indicated that this anti-body labeled with iodine-125 would localized in the tumor cells of high grade gliomas of the brain.
- Trial name
- NCT00589706
- Testing
- MAb-425
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Drexel University College of Medicine
Cervical Cancer
Acceptability and Validity of Self Sampling for High Risk HPV Detection Among Women in Maharashtra
The study goals are, 1. To determine the test characteristics (sensitivity, specificity, positive predictive value, negative predictive value, false positivity rates, false negativity rates) of health personnel collected and self…
- Trial name
- HPV (NCT03386695)
- Testing
- Education by Pamphlets, Health education programme
- Where
- India
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
Esophageal Neoplasms
KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
The goal of this observational study is to test the clinical efficacy of "KCNA3 and OTOP2 gene methylation combined detection kit (fluorescence PCR method)"in esophageal cancer and high-grade esophageal neoplasia auxiliary…
- Trial name
- NCT05680077
- Testing
- KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
- Where
- China
- Volunteers
- 1,116 people
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Breast Fibroadenoma
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
This is a multi-center, crossover study with cluster randomization and a planned accrual of 300 patients with diagnosed breast fibroadenoma (One fibroadenoma treated per patient).
- Trial name
- NCT03742401
- Testing
- Surgery, HIFU (Echopulse)
- Where
- 12 sites in France
- Volunteers
- 2 people
- Sponsor
- Theraclion
Prostate Cancer
177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and…
- Trial name
- PSMA-ADJUVO (NCT06449781)
- Testing
- Lutetium (177Lu) vipivotide tetraxetan
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Breast Cancer
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Women with breast cancer who are not eligible for breast conserving surgery or who have node-involvement are sometimes treated with chemotherapy up front, in hopes of allowing for a woman to keep her breast and decreasing the…
- Trial name
- NCT00462865
- Testing
- Gemcitabine and Capecitabine and Avastin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Breast Cancer
High Risk Breast Cancer Screening Program
Objectives: To screen population with high risk for breast cancer To promote the concept and importance of surveillance mammography To find out the incidence of breast cancer in population who are in high risk for breast cancer…
- Trial name
- NCT00509509
- Where
- Hong Kong
- Sponsor
- Organisation for Oncology and Translational Research
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
This study will be aimed at investigating the effectiveness of a treatment for brain tumors called Photodynamic Therapy, or PDT.
- Trial name
- NCT01966809
- Testing
- Photofrin photodynamic therapy.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Harry T Whelan, MD
Epithelial Ovarian Cancer
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or…
- Trial name
- TREVI-OC-01 (NCT07218809)
- Testing
- AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel
- Where
- 299 sites in United States, Australia and 22 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Glioma, High Grade
A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
This clinical trial is designed to evaluate the safety and efficacy of a universal mRNA vaccine targeting a panel of glioma-associated mutations in patients with recurrent or progressive high-grade glioma.
- Trial name
- NCT07306299
- Testing
- Glioma-related multi-target mRNA vaccines
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Phase II trial to study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer.
- Conditions
- Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma
- Trial name
- NCT00004221
- Testing
- Carboplatin, Cyclophosphamide, Filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gynecologic Oncology Group
Pancreatic Ductal Adenocarcinoma, Hereditary Diseases
Pancreatic Cancer Screening in a Population at High Risk
Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Hereditary Diseases, Pancreatitis, Chronic
- Trial name
- ScrePan (NCT06330441)
- Testing
- endoscopic ultrasonography, magnetic resonance, laboratory examination
- Where
- Czechia
- Volunteers
- 700 people
- Sponsor
- Masaryk Memorial Cancer Institute
Mediastinal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Mediastinal Cancer, Metastatic Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00003941
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 222 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Infertility and at High Risk of OHSS
Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk…
- Trial name
- NCT02022241
- Testing
- triptorelin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chenshiling
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Triple Negative Breast Cancer
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who…
- Trial name
- NeoCARD (NCT06845319)
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
Breast Cancer
Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer
The investigators combined postoperative radiotherapy with CDK4/6 inhibitors ± endocrine adjuvant therapy to explore the tolerability and safety of this treatment regimen in HR+/HER2- postoperative high-risk breast cancer…
- Trial name
- NCT07446686
- Testing
- CDK4/6 inhibitor±endocrine therapy drug±OFS treatment combined with synchronous radiotherapy
- Volunteers
- 30 people
- Sponsor
- Guizhou Provincial People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.